Dec 2022 $5 M No. 7 $2 to $10 million 1
Aridis Pharmaceuticals, Inc.: Raise no. 7, Dec 2022 × Investors in this round 1 investor had bought by the notice of Dec 20, 2022: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Fred Kurland · Executive Officer · Chief Financial Officer Vu Truong · Executive Officer · Chief Executive Officer and Chief Scientific Officer Craig Gibbs · Director · Chairman of Board of Directors Eric Patzer · Director · Chairman John Hamilton · Director Robert Ruffolo · Director Susan Windham-Bannister · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Vu Truong, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 20, 2022. Read the notice at the SEC .
equity SEC Oct 2022 $8 M No. 6 $2 to $10 million 1
Aridis Pharmaceuticals, Inc.: Raise no. 6, Oct 2022 × Investors in this round 1 investor had bought by the notice of Oct 12, 2022: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eric Patzer · Executive Officer, Director · Secretary, Chairman of the Board of Directors Fred Kurland · Executive Officer · Chief Financial Officer Vu Truong · Executive Officer, Director · Chief Executive Officer, Director Craig Gibbs · Director John Hamilton · Director Robert Ruffolo, Jr. · Director Susan Windham-Bannister · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Vu Truong, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 12, 2022. Read the notice at the SEC .
equity, options SEC Oct 2020 $8 M No. 5 $2 to $10 million 8
Aridis Pharmaceuticals, Inc.: Raise no. 5, Oct 2020 × Investors in this round 8 investors had bought by the notice of Oct 26, 2020: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $590,038
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eric Patzer · Executive Officer, Director · Secretary, Chairman of the Board of Directors Mike Nazak · Executive Officer · Chief Financial Officer Vu Troung · Executive Officer, Director · Chief Executive Officer, Director Craig Gibbs · Director John Hamilton · Director Robert Ruffolo, Jr. · Director Susan Windham-Bannister · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Arcadia Securities, LLC (CRD 44656) · New York, New York Sold in MD, NJ Cantor Fitzgerald & Co. (CRD 134) · New York, New York Sold in MD, NJ Signed by Vu Truong, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 26, 2020. Read the notice at the SEC .
equity, options SEC Dec 2016 $14 M No. 4 $10 to $50 million 14
Aridis Pharmaceuticals, Inc.: Raise no. 4, Dec 2016 × Investors in this round 14 investors had bought by the notice of Dec 15, 2016: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $14 M of $25 M offered; $11 M still to sell
Smallest investment taken $25,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,364,270
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eric Patzer · Executive Officer, Director · Secretary, Chairman of the Board of Directors Fred Kurland · Executive Officer · Chief Financial Officer Paul-Andre de Lame · Executive Officer · Chief Medical Officer Vu Troung · Executive Officer, Director · Chief Executive Officer, Director Craig Gibbs · Director Isaac Blech · Director · Vice Chairman John Hamilton · Director Robert Coughlin · Director Robert Ruffolo, Jr. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Merchant Capital, a division of Maxim Group LLC (CRD 120708) · New York, New York Sold in AL, AZ, CA, DC, FL, IL, MN, NM, NV, NY, TX Remarks in the notice On fees: “The placement agent will also recieve a warrant to purchase Series A Convertible Preferred Stock or common stock at the same exercise price as investors.”Signed by Vu Truong, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 15, 2016. Read the notice at the SEC .
equity, options SEC Aug 2016 $15 M No. 3 $10 to $50 million 133
Aridis Pharmaceuticals, Inc.: Raise no. 3, Aug 2016 × Investors in this round 133 investors had bought by the notice of Aug 19, 2016: 133 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $15 M of $40 M offered; $25 M still to sell
Smallest investment taken $50,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,521,624
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Eric Patzer · Executive Officer, Director · Secretary, Chairman of the Board of Directors Fred Kurland · Executive Officer · Chief Financial Officer Paul-Andre de Lame · Executive Officer · Chief Medical Officer Vu Truong · Executive Officer, Director · Chief Executive Officer, Director Craig K. Gibbs · Director Isaac R. Blech · Director · Vice Chairman John K. Hamilton · Director Robert K. Coughlin · Director Robert R. Ruffolo, Jr. · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Merchant Capital, a division of Maxim Group LLC (CRD 120708) · New York, New York Sold in AZ, CA, CO, CT, DC, DE, FL, HI, IL, IN, KS, KY, MA, MD, MI, MN, MO, NH, NJ, NV, NY, PA, RI, SC, TX, VT, WI, WY, and outside the US Remarks in the notice On fees: “The placement agent also received a warrant to purchase Series A Convertible Preferred Stock or common stock at the same exercise price as investors.”Signed by Vu Truong, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 19, 2016. Read the notice at the SEC .
equity, options SEC Nov 2015 $3 M No. 2 $2 to $10 million 6
Aridis Pharmaceuticals, Inc.: Raise no. 2, Nov 2015 × Investors in this round 6 investors had bought by the notice of Nov 24, 2015: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $3 M of $4 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Fred Kurland · Executive Officer · Chief Financial Officer Paul-Andre de Lame · Executive Officer · Chief Medical Officer Vu Truong · Executive Officer, Director · Chief Executive Officer and Chief Scientific Officer Craig Gibbs · Director Eric Patzer · Director · Chairman of the Board of Directors John Hamilton · Director Robert Coughlin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Vu Truong, Chief Executive Officer and Chief Scientific Officer. Source: SEC Form D, newest notice filed Nov 24, 2015. Read the notice at the SEC .
debt, options SEC May 2014 $4 M No. 1 $2 to $10 million 9
Aridis Pharmaceuticals, Inc.: Raise no. 1, May 2014 × Investors in this round 9 investors had bought by the notice of Jul 17, 2014: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken $250,000
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them, other: The company issued units consisting of 1 convertible note and 1 warrant Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John Borgeson · Executive Officer · Chief Financial Officer (Acting) Vu Truong · Executive Officer, Director · Chief Executive Officer Eric Patzer · Director Fred Kurland · Director Robert Coughlin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Eric Patzer, Chairman. Source: SEC Form D, newest notice filed Jul 17, 2014. Read the notice at the SEC .
debt, options SEC